CN110974977A - Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules - Google Patents
Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules Download PDFInfo
- Publication number
- CN110974977A CN110974977A CN201911300810.8A CN201911300810A CN110974977A CN 110974977 A CN110974977 A CN 110974977A CN 201911300810 A CN201911300810 A CN 201911300810A CN 110974977 A CN110974977 A CN 110974977A
- Authority
- CN
- China
- Prior art keywords
- paeonol
- drying
- solution
- moutan bark
- moutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D1/00—Evaporating
- B01D1/16—Evaporating by spraying
- B01D1/18—Evaporating by spraying to obtain dry solids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention discloses a drying method of a paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula particles, which is used for drying a medium containing paeonol active ingredients, wherein the medium comprises a paeonol inclusion solution included by β -cyclodextrin, and the drying adopts spray drying.
Description
Technical Field
The invention relates to the technical field of preparation of traditional Chinese medicine formula granules, in particular to a drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules.
Background
Cortex moutan is dried root bark of Paeonia suffruticosa Andr. belonging to Ranunculaceae, is a traditional common medicinal material, and is mainly produced in Anhui copper Ling, Chongqing Teijiang and Shandong lotus leaf, etc.; slightly cold in nature, bitter and pungent in flavor, entering heart, liver and kidney meridians; it is listed as a Chinese medicine from Shen nong Ben Cao Jing (Shen nong's herbal Jing), and has the actions of clearing heat and cooling blood, and promoting blood circulation to remove blood stasis. Can be used for treating heat entering nutrient-blood, warm toxic and macula, hematemesis and epistaxis, night fever and early coolness, no sweating and bone steaming, amenorrhea and dysmenorrhea, traumatic injury and pain, carbuncle, swelling and sore. Modern researches show that cortex moutan contains phenol and its glycosides, monoterpene and its glycosides, and triterpene, sterol and its glycosides, flavone, organic acid, coumarin, volatile oil, etc. as main components. Wherein the phenol and the phenol glycosides are compounds with high content in cortex moutan, and are mainly a series of glycosides derived from paeonol as mother nucleus.
Recent pharmacological research shows that the tree peony bark has the functions of anticoagulation, blood pressure reduction, inflammation resistance, central nervous system inhibition, immunity regulation and the like. The main bioactive components of the tree peony bark comprise paeonol, total paeoniflorin, tree peony bark polysaccharide and the like, wherein the pharmacological action of the tree peony bark is most extensive. Paeonol is the main active ingredient of cortex moutan, can obviously inhibit the formation of atherosclerotic plaque, has obvious effects of lowering blood pressure, protecting myocardial cells, resisting arrhythmia and changing blood rheological property, and has the effects of resisting convulsion, protecting cerebral hemorrhage and ischemia reperfusion injury, improving the cellular immunity of organisms, protecting liver, resisting bacteria and diminishing inflammation and the like in the aspect of the central nervous system. Therefore, the quality of the moutan bark is controlled by the content of paeonol which is commonly used at present.
The traditional Chinese medicine formula particle is a particle which is prepared by taking traditional Chinese medicine decoction pieces as raw materials and utilizing modern production technology according to a certain production process and is used for clinically flexible dispensing. The traditional Chinese medicine decoction is used under the guidance of the traditional Chinese medicine theory, is based on clinical use of the traditional Chinese medicine decoction, has the characteristics of convenience in taking, easiness in storage, easiness in carrying, controllable quality and the like compared with the traditional Chinese medicine decoction, and accords with the life rhythm of modern people.
The cortex moutan formula particle is a formula particle processed from dried root bark of Paeonia suffruticosa Andr of Ranunculaceae, and can be flexibly prepared according to the prescription of a doctor.
In the prior common production process of the moutan bark formula particles, paeonol contained in the moutan bark formula particles is specially collected, included, dried at low temperature and added, but the paeonol is required to be stood at low temperature after inclusion to be crystallized and completely separated out, and then is filtered, and finally is dried at low temperature, the procedures are complex to operate, the subsequent mixing and granulation by adding concentrated solution dry paste powder can be carried out at least 2 to 3 days in production, the production period is long, and the production efficiency is low.
Disclosure of Invention
Aiming at the technical problems of long production period and low production efficiency of the existing production process of the moutan bark formula particle, the invention provides a drying method of a paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark formula particle.
Aiming at the problems, the technical key point of the drying method of the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark formula particles is that the drying method of the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark formula particles is used for drying a medium containing effective components of the paeonol, the medium comprises a paeonol inclusion solution which is included by β -cyclodextrin, and the drying adopts spray drying.
In the prior art, the common preparation process of the moutan bark formula particle generally has longer production period or higher cost. In the existing optional process, if yield is considered, freeze drying is adopted, so that paeonol is almost free from loss, but the cost is extremely high, and the method is not suitable for large-scale production; in consideration of efficiency, the existing preparation of the moutan bark extract adopts a spray drying mode, and the specific drying object is generally a mixed solution obtained by mixing volatile component paeonol obtained by condensation with a concentrated solution.
According to the scheme, specific drying objects are different from paeonol in the prior art that spray drying is directly carried out without inclusion, β -cyclodextrin inclusion paeonol inclusion liquid is adopted, and different from the prior art, in a specific process route, an inclusion process is added in an extraction → drying process, so that the problem that when the non-included paeonol and concentrated solution are subjected to spray drying, the loss is huge because the concentrated solution is high in temperature (generally 80-90 ℃) and the paeonol is dissolved in the concentrated solution, the air inlet temperature (generally 180-200 ℃) and the air outlet temperature (generally 70-90 ℃) are also high, and the non-included paeonol is volatilized along with water in a spray tower is solved, the low-temperature drying time is generally more than 48 hours, the freeze drying is generally more than 24 hours, the spray drying does not need 24 hours required by cold storage separation, the spray drying is completed for 3-4 hours, and the spray drying yield is improved by only by adopting a spray drying method, so that the drying time is saved by more than 2.5d compared with the single-batch production, the freeze drying time is generally more than that the spray drying time is equal to more than 48 hours, the spray drying efficiency is improved by adopting the spray drying method, and the spray drying efficiency is improved by more than 20 percent.
The further technical scheme is as follows:
in consideration of the characteristic of huge existing general spray drying systems, the β -cyclodextrin included paeonol inclusion liquid contains less solid, for example, when the paeonol inclusion liquid is directly subjected to spray drying, the solid content remained in the spray drying system in the specific spray drying process is large, and the residual solid is continuously heated to volatilize and lose the paeonol which is not included, so that the paeonol yield is comprehensively low.
As a technical scheme which can ensure that the spray drying can be smoothly carried out and can ensure that the loss of the paeonol inclusion compound can be accepted in the temperature, the method is characterized by comprising the following steps: in the process of ensuring the quality of the product, the air inlet temperature of the spraying is controlled to be 120-150 ℃, and the air outlet temperature is controlled to be 60-70 ℃.
In view of improving the yield of paeonol, it is preferable that: the air inlet temperature of the spraying is controlled to be 120-130 ℃, and the air outlet temperature is controlled to be 60-65 ℃.
In view of improving the yield of paeonol, it is preferable that: the air inlet temperature of the spraying is controlled to be 140-150 ℃, and the air outlet temperature is controlled to be 65-70 ℃.
More specifically, the following settings are set: the moutan bark concentrated solution is: taking raw materials, adding water to extract to obtain an extracting solution, and concentrating under reduced pressure to obtain a concentrated solution.
More specifically, the paeonol inclusion liquid is obtained by crystallizing paeonol distillate collected in the water extraction process and including the paeonol distillate with β -cyclodextrin.
Considering the influence of temperature on inclusion, β -cyclodextrin increases in solubility with the rise of temperature, paeonol inclusion compound gradually opens the ring to dissolve out the included paeonol, and the inclusion effect is influenced, meanwhile, paeonol volatilization loss is sensitive to temperature, the temperature of the paeonol inclusion compound is 40-45 ℃ when the paeonol concentrated solution and the paeonol inclusion compound solution are mixed to obtain the mixed solution, and the temperature of the paeonol inclusion compound solution is 40-45 ℃ before the paeonol inclusion compound solution is used for mixing;
when the cortex moutan concentrated solution and the paeonol inclusion solution are mixed to obtain the mixed solution, the temperature of the cortex moutan concentrated solution is 40-45 ℃, the scheme can obtain an ideal inclusion effect, the paeonol β -cyclodextrin inclusion compound is sprayed at low temperature, the inclusion compound is stable in the spraying process, the ring opening is less, the loss is less, the transfer rate is high, when the temperature is reduced to be below 40 ℃ or room temperature, a large polymer can be formed due to the reduction of the dissolution of β -cyclodextrin, and the water content of atomized head blocking or sprayed dry paste powder is higher during low-temperature spraying.
As described above, in consideration of the influence of the solid remaining in the spray system on the yield of paeonol, it is preferable to use a cortex moutan extract fluid extract including a concentrated cortex moutan solution as a drying object. In order to ensure that the added moutan bark concentrated solution does not have substantial influence on the whole spraying time under the condition of ensuring the yield of the paeonol, the method is set as follows: mixing to obtain cortex moutan concentrated solution of cortex moutan extract fluid extract, wherein the solid content is greater than or equal to 30 kg.
In order to improve the utilization rate of raw materials such as moutan bark medicinal materials, moutan bark decoction pieces and the like as far as possible, the mixing and granulating link is carried out as soon as possible, the moutan bark concentrated solution is obtained by taking the raw materials and adding water to extract the obtained extracting solution and concentrating the extracting solution under reduced pressure, and the paeonol inclusion solution is obtained by crystallizing paeonol distillate collected in the water adding extraction process and including the paeonol distillate with β -cyclodextrin;
in the spray drying process, drying the cortex moutan extract fluid extract by stages:
stage one: the air inlet temperature of the spraying is controlled to be 120-150 ℃, and the air outlet temperature is controlled to be 60-70 ℃; drying the cortex moutan extract to obtain a fluid extract;
and a second stage: after the first stage is finished, controlling the air inlet temperature of spraying to be 170-180 ℃ and the air outlet temperature to be 80-90 ℃; the drying object is the residual cortex moutan concentrated solution after the cortex moutan extract fluid extract is prepared. After the second stage is finished, spray dried paste powder is obtained by collecting powder, crushing, sieving and mixing.
The invention has the following beneficial effects:
in the scheme, specific drying objects are different from the paeonol in the prior art that spray drying is directly carried out without inclusion, and the paeonol inclusion liquid included by β -cyclodextrin is adopted, so that the yield of the paeonol is increased to more than 70% from 20-40% which can be achieved by the existing spray drying, the preparation quality of the moutan bark formula particles can be ensured by increasing the yield of the paeonol, and the advantage of improving the production efficiency of the moutan bark formula particles is brought out by the application of the spray drying in the preparation of the moutan bark formula particles.
Detailed Description
The present invention will be described in further detail with reference to the following examples, but the present invention is not limited to the following examples:
example 1:
a drying method of a paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula particles is used for drying a medium containing paeonol active ingredients, wherein the medium comprises a paeonol inclusion solution included by β -cyclodextrin, and the drying adopts spray drying.
In the prior art, the common preparation process of the moutan bark formula particle generally has longer production period or higher cost. In the existing optional process, if yield is considered, freeze drying is adopted, so that paeonol is almost free from loss, but the cost is extremely high, and the method is not suitable for large-scale production; in consideration of efficiency, the existing preparation of the moutan bark extract adopts a spray drying mode, and the specific drying object is generally a mixed solution obtained by mixing volatile component paeonol obtained by condensation with a concentrated solution.
In the scheme, specific drying objects are different from the paeonol in the prior art that spray drying is directly carried out without inclusion, and the paeonol inclusion liquid included by β -cyclodextrin is adopted, so that the yield of the paeonol is increased to more than 70% from 20-40% which can be achieved by the existing spray drying, the preparation quality of the moutan bark formula particles can be ensured by increasing the yield of the paeonol, and the advantage of improving the production efficiency of the moutan bark formula particles is brought out by the application of the spray drying in the preparation of the moutan bark formula particles.
Example 2:
this example is further defined on the basis of example 1:
in consideration of the characteristic of huge existing general spray drying systems, the β -cyclodextrin included paeonol inclusion liquid contains less solid, for example, when the paeonol inclusion liquid is directly subjected to spray drying, the solid content remained in the spray drying system in the specific spray drying process is large, and the residual solid is continuously heated to volatilize and lose the paeonol which is not included, so that the paeonol yield is comprehensively low.
As a technical scheme which can ensure that the spray drying can be smoothly carried out and can ensure that the loss of the paeonol inclusion compound can be accepted in the temperature, the method is characterized by comprising the following steps: in the process of ensuring the quality of the product, the air inlet temperature of the spraying is controlled to be 120-150 ℃, and the air outlet temperature is controlled to be 60-70 ℃.
More specifically, the following settings are set: the moutan bark concentrated solution is: taking raw materials, adding water to extract to obtain an extracting solution, and concentrating under reduced pressure to obtain a concentrated solution.
More specifically, the paeonol inclusion liquid is obtained by crystallizing paeonol distillate collected in the water extraction process and including the paeonol distillate with β -cyclodextrin.
Considering the influence of temperature on inclusion, β -cyclodextrin increases in solubility with the rise of temperature, paeonol inclusion compound gradually opens the ring to dissolve out the included paeonol, and the inclusion effect is influenced, meanwhile, paeonol volatilization loss is sensitive to temperature, the temperature of the paeonol inclusion compound is 40-45 ℃ when the paeonol concentrated solution and the paeonol inclusion compound solution are mixed to obtain the mixed solution, and the temperature of the paeonol inclusion compound solution is 40-45 ℃ before the paeonol inclusion compound solution is used for mixing;
when the cortex moutan concentrated solution and the paeonol inclusion solution are mixed to obtain the mixed solution, the temperature of the cortex moutan concentrated solution is 40-45 ℃. The proposal can obtain ideal inclusion effect.
As described above, in consideration of the influence of the solid remaining in the spray system on the yield of paeonol, it is preferable to use a cortex moutan extract fluid extract including a concentrated cortex moutan solution as a drying object. In order to ensure that the added moutan bark concentrated solution does not have substantial influence on the whole spraying time under the condition of ensuring the yield of the paeonol, the method is set as follows: mixing to obtain cortex moutan concentrated solution of cortex moutan extract fluid extract, wherein the solid content is greater than or equal to 30 kg.
In order to improve the utilization rate of raw materials such as moutan bark medicinal material, moutan bark decoction pieces and the like as far as possible, the moutan bark concentrated solution is obtained by taking the raw materials and adding water for extraction to obtain an extracting solution and concentrating the extracting solution under reduced pressure, and the paeonol inclusion solution is obtained by crystallizing paeonol distillate collected in the water adding extraction process and including the paeonol distillate with β -cyclodextrin;
in the spray drying process, drying the cortex moutan extract fluid extract by stages:
stage one: the air inlet temperature of the spraying is controlled to be 120-150 ℃, and the air outlet temperature is controlled to be 60-70 ℃; drying the cortex moutan extract to obtain a fluid extract;
and a second stage: after the first stage is finished, controlling the air inlet temperature of spraying to be 170-180 ℃ and the air outlet temperature to be 80-90 ℃; the drying object is the residual cortex moutan concentrated solution after the cortex moutan extract fluid extract is prepared. After the second stage is finished, spray dried paste powder is obtained by collecting powder, crushing, sieving and mixing.
Example 3:
this embodiment provides a more specific scheme based on embodiment 2: in view of improving the yield of paeonol, it is preferable that: the air inlet temperature of the spraying is controlled to be 120-130 ℃, and the air outlet temperature is controlled to be 60-65 ℃.
Example 4:
this embodiment provides a more specific scheme based on embodiment 2: in view of improving the yield of paeonol, it is preferable that: the air inlet temperature of the spraying is controlled to be 140-150 ℃, and the air outlet temperature is controlled to be 65-70 ℃.
Example 5:
the embodiment provides a specific implementation manner:
the preparation method comprises the steps of taking 300kg of tree peony bark, adding water for extraction, collecting paeonol distillate simultaneously, filtering an extracting solution, carrying out reduced pressure concentration to obtain tree peony bark concentrated solution, taking the paeonol distillate obtained in the water adding extraction process, refrigerating and standing, crystallizing, including with β -cyclodextrin to obtain paeonol inclusion solution, keeping the temperature at 40-42 ℃, taking 150kg of tree peony bark extract concentrated solution (wherein the solid content is about 38kg), heating to 40 ℃, adding the tree peony bark phenol inclusion solution, mixing uniformly to obtain tree peony bark extract physical flow extract, carrying out spray drying, controlling the spray air inlet temperature at 120-130 ℃, controlling the air outlet temperature at 60-65 ℃, drying the tree peony bark extract physical flow extract, continuously spraying the residual tree peony bark concentrated solution, adjusting the air inlet temperature to 170-180 ℃, adjusting the air outlet temperature to 80-90 ℃, collecting powder, crushing, and sieving to obtain spray dried powder.
In the present example, the yield of the spray drying of paeonol is 75.3% (the yield of paeonol obtained by steam distillation is more than 90%, the yield of the inclusion of paeonol β -cyclodextrin is more than 90%, and the loss of spray drying ring is only about 20%), which is slightly higher than the average yield (73.6%) of the inclusion liquid obtained by refrigeration, crystallization, suction filtration and low-temperature drying.
Example 6:
the embodiment provides a specific implementation manner:
300kg of tree peony bark is taken, water is added for extraction, meanwhile, paeonol distillate is collected, an extracting solution is filtered and decompressed for concentration, tree peony bark concentrated solution is obtained, the tree peony bark distillate obtained in the water adding and extracting process is taken, refrigerated and stood for crystallization, β -cyclodextrin is used for inclusion, tree peony bark inclusion liquid is obtained, the temperature is kept at 42-44 ℃, 150kg of tree peony bark extract concentrated solution (wherein the solid content is about 38kg) is taken, the temperature is heated to 43 ℃, the tree peony bark inclusion liquid is added, the tree peony bark extract physical flow extract is obtained by even mixing, then spray drying is carried out, the spray air inlet temperature is controlled at 130-140 ℃, the air outlet temperature is controlled at 63-68 ℃, the tree peony bark extract physical flow extract is dried, the residual tree peony bark concentrated solution is continuously sprayed, the air inlet temperature is adjusted to 170-180 ℃, the air outlet temperature is adjusted to 80.
In the embodiment, the yield of the spray drying of the paeonol is 72.9 percent (the yield of the paeonol obtained by steam distillation is more than 90 percent, the inclusion yield of the paeonol β -cyclodextrin is more than 90 percent, and the spray drying ring has only about 20 percent loss), and has no obvious difference with the average yield (73.6 percent) of the inclusion liquid obtained by refrigeration, crystallization, suction filtration and low-temperature drying.
Example 7:
the embodiment provides a specific implementation manner:
300kg of tree peony bark is taken, water is added for extraction, meanwhile, paeonol distillate is collected, an extracting solution is filtered and decompressed for concentration, tree peony bark concentrated solution is obtained, the tree peony bark distillate obtained in the water adding and extracting process is taken, refrigerated and stood for crystallization, β -cyclodextrin is used for inclusion, tree peony bark inclusion liquid is obtained, the temperature is kept at 43-45 ℃, 120kg of tree peony bark extract concentrated solution (the solid content is about 32kg) is taken, the temperature is heated to 45 ℃, the tree peony bark inclusion liquid is added, the tree peony bark extract physical flow extract is obtained by even mixing, then spray drying is carried out, the spray air inlet temperature is controlled to be 140-150 ℃, the air outlet temperature is controlled to be 65-70 ℃, the tree peony bark extract physical flow extract is dried, the residual tree peony bark concentrated solution is continuously sprayed, the air inlet temperature is adjusted to be 170-180 ℃, the air outlet temperature is adjusted.
In this example, the yield of paeonol spray-dried is 74.1% (the yield of paeonol obtained by steam distillation is above 90%, the yield of paeonol β -cyclodextrin inclusion is above 90%, and the loss of spray-dried ring is only about 20%), which is slightly higher than the average yield (73.6%) of inclusion liquid obtained by refrigeration, crystallization, suction filtration and low-temperature drying.
The foregoing is a more detailed description of the present invention in connection with specific preferred embodiments thereof, and it is not intended that the specific embodiments of the present invention be limited to these descriptions. For those skilled in the art to which the invention pertains, other embodiments that do not depart from the gist of the invention are intended to be within the scope of the invention.
Claims (10)
1. A drying method of a paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula particles is used for drying a medium containing paeonol active ingredients, and is characterized in that the medium comprises a paeonol inclusion solution which is included by β -cyclodextrin, and the drying adopts spray drying.
2. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 1, wherein the medium further comprises a moutan bark concentrate, the object of spray drying is a moutan bark extract fluid extract, and the moutan bark extract fluid extract is a mixed solution comprising the moutan bark concentrate and the paeonol inclusion compound.
3. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 2, wherein the air inlet temperature of the spray is controlled to be 120-150 ℃ and the air outlet temperature is controlled to be 60-70 ℃ during the spray drying process.
4. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 3, wherein the air inlet temperature of the spray is controlled to be 120-130 ℃ and the air outlet temperature is controlled to be 60-65 ℃.
5. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark formula particle as claimed in claim 3, wherein the air inlet temperature of the spraying is controlled to be 140-150 ℃ and the air outlet temperature is controlled to be 65-70 ℃.
6. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark dispensing granule as claimed in claim 2, wherein the moutan bark concentrated solution is a concentrated solution obtained by extracting the raw materials with water and concentrating the obtained extract under reduced pressure.
7. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 6, wherein the paeonol inclusion solution is an inclusion solution obtained by crystallizing the paeonol distillate collected in the water extraction process and including the paeonol distillate with β -cyclodextrin.
8. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 7, wherein the temperature of the paeonol inclusion solution is 40 ℃ to 45 ℃ when the moutan bark concentrated solution and the paeonol inclusion solution are mixed to obtain the mixed solution, and the temperature of the paeonol inclusion solution is 40 ℃ to 45 ℃ before the paeonol inclusion solution is used for mixing;
when the cortex moutan concentrated solution and the paeonol inclusion solution are mixed to obtain the mixed solution, the temperature of the cortex moutan concentrated solution is 40-45 ℃.
9. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark granule as claimed in claim 2, wherein the solid content of the moutan bark extract is greater than or equal to 30kg in the moutan bark concentrated solution mixed to obtain the moutan bark extract fluid extract.
10. The method for drying the paeonol β -cyclodextrin inclusion compound in the preparation of the moutan bark formula particle as claimed in claim 9, wherein the moutan bark concentrated solution is obtained by adding water to extract an extracting solution and concentrating the extracting solution under reduced pressure, and the paeonol inclusion compound is obtained by crystallizing a paeonol distillate collected in the water extraction process and including the paeonol distillate with β -cyclodextrin;
in the spray drying process, drying the cortex moutan extract fluid extract by stages:
stage one: the air inlet temperature of the spraying is controlled to be 120-150 ℃, and the air outlet temperature is controlled to be 60-70 ℃; drying the cortex moutan extract to obtain a fluid extract;
and a second stage: after the first stage is finished, controlling the air inlet temperature of spraying to be 170-180 ℃ and the air outlet temperature to be 80-90 ℃; the drying object is the residual cortex moutan concentrated solution after the cortex moutan extract fluid extract is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911300810.8A CN110974977A (en) | 2019-12-17 | 2019-12-17 | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911300810.8A CN110974977A (en) | 2019-12-17 | 2019-12-17 | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110974977A true CN110974977A (en) | 2020-04-10 |
Family
ID=70094711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911300810.8A Pending CN110974977A (en) | 2019-12-17 | 2019-12-17 | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110974977A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028341A (en) * | 2021-11-17 | 2022-02-11 | 北京康仁堂药业有限公司 | Cortex moutan formula particle and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933576A (en) * | 2012-08-16 | 2014-07-23 | 湖北天圣康迪制药有限公司 | Preparation method of paeonol preparation |
| CN106974971A (en) * | 2017-02-28 | 2017-07-25 | 吉林修正药业新药开发有限公司 | The preparation method and its quality determining method of a kind of Cortex Moutan Dispersing Granules |
| CN108403791A (en) * | 2018-03-07 | 2018-08-17 | 浙江工业大学 | Preparation method of cortex moutan extract with high paeonol content |
-
2019
- 2019-12-17 CN CN201911300810.8A patent/CN110974977A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933576A (en) * | 2012-08-16 | 2014-07-23 | 湖北天圣康迪制药有限公司 | Preparation method of paeonol preparation |
| CN106974971A (en) * | 2017-02-28 | 2017-07-25 | 吉林修正药业新药开发有限公司 | The preparation method and its quality determining method of a kind of Cortex Moutan Dispersing Granules |
| CN108403791A (en) * | 2018-03-07 | 2018-08-17 | 浙江工业大学 | Preparation method of cortex moutan extract with high paeonol content |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028341A (en) * | 2021-11-17 | 2022-02-11 | 北京康仁堂药业有限公司 | Cortex moutan formula particle and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108822068A (en) | A method of preparing wild blueberry anthocyanidin | |
| CN103145872A (en) | Panax notoginseng polysaccharide with low ash content and preparation method of polysaccharide | |
| CN102119964B (en) | A kind of prevention and the extract for the treatment of angina pectoris, their Preparation method and use | |
| CN105902695A (en) | Novel method for preparing double-violet injection | |
| CN110974977A (en) | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules | |
| CN108403791B (en) | Preparation method of cortex moutan extract with high paeonol content | |
| CN109717445B (en) | Sweet taste composition and preparation method and application thereof | |
| CN100463890C (en) | Highly effective extraction method for magnolol and honokiol crude extract | |
| CN102114182B (en) | Compound preparation for resisting heat stress and heat fatigue | |
| CN105906538A (en) | Method for continuously extracting alliin, garlic polysaccharide and odorless garlic powder by taking fresh garlic as raw material | |
| CN103169095A (en) | Method for preparing barbary wolfberry fruit powder by adding chrysanthemum extract liquid | |
| CN103694212A (en) | Purifying method for amentoflavone | |
| CN110664764A (en) | Single-flavor low-temperature vacuum drying extraction powder and extraction method thereof | |
| CN110227091A (en) | The extraction of paniculate swallowwort medicinal ingredient and its granule and preparation method | |
| CN108785358A (en) | A kind of preparation method of Honegsukle flower P.E | |
| CN109568402A (en) | A kind of preparation method of white peony root dispensing granule | |
| CN111018929B (en) | Process for extracting and separating isocoryzanol | |
| CN103550275A (en) | Method for extracting saussurea involucrate essences | |
| CN109464317B (en) | Composition containing biota orientalis extract and preparation method and application thereof | |
| CN114196479A (en) | Low-temperature extraction process of ginkgo leaves | |
| CN109568383A (en) | A kind of preparation method of Radix Glycyrrhizae or honey-fried licorice root dispensing granule | |
| CN115093452B (en) | A method for preparing folium Platycladi extract | |
| CN110585260A (en) | Single-ingredient freeze-dried powder and preparation method thereof | |
| CN109568449A (en) | A kind of preparation method of viola mandshurica granule | |
| CN109602781A (en) | A kind of preparation method of Honegsukle flower P.E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200410 |